This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
STERIS' (STE) Earnings & Revenues Surpass Estimates in Q1
by Zacks Equity Research
STERIS' (STE) first-quarter fiscal 2021 results reflect strong performance by the Life Sciences segment despite the coronavirus-led economic crisis.
Hologic (HOLX) Q3 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Hologic (HOLX) exhibited robust segmental growth in third-quarter fiscal 2020 driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.
Hologic (HOLX) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of 108.33% and 37.11%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
T2 Biosystems (TTOO) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
T2 Biosystems' (TTOO) second-quarter results are likely to reflect growth in product revenues.
Invitae (NVTA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Genetic testing is likely to drive Invitae's (NVTA) Q2 earnings.
Aphria (APHA) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Aphria's (APHA) fiscal fourth-quarter results are likely to reflect higher sales from medical and adult-use cannabis products.
Stryker (SYK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) second-quarter results are likely to reflect weak segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.
Baxter (BAX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) second-quarter performance is likely to reflect growth in its five global business units.
DaVita (DVA) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Solid performance within net dialysis and related lab patient service segment is likely to have contributed to DaVita's (DVA) top line in Q2.
Cerner (CERN) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Cerner's (CERN) second-quarter results are likely to reflect solid show by Subscriptions, Managed Services and Licensed software segments.
DexCom (DXCM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) second-quarter results are likely to reflect rising global awareness of its real-time CGM.
Quidel (QDEL) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Quidel (QDEL) is likely to have witnessed an uptick in rapid immunoassay revenues in Q2.
PerkinElmer (PKI) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) second-quarter results are likely to reflect strong performance at Diagnostics segment. However, forex remained a woe.
Ecolab (ECL) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) Global Industrial segment is likely to have gained from the Water, Food & Beverage and Life Sciences sub-units in Q2.
Hologic (HOLX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Diagnostics Aid Hologic (HOLX) Q3 Earnings Amid Coronavirus?
by Zacks Equity Research
Strength in segmental business is likely to have aided Hologic's (HOLX) performance in third-quarter fiscal 2020 amid the coronavirus-led economic doldrums.
Hologic Expands Product Portfolio With New Ultrasound System
by Zacks Equity Research
Hologic's (HOLX) latest cart-based ultrasound system enhances efficiency and accuracy to better meet the requirements of breast imagers and optimize patient care.
Myriad Genetics Rides on EndoPredict Amid Coronavirus Crisis
by Zacks Equity Research
Myriad Genetics (MYGN) expects to register an uptick in hereditary cancer volumes on account of its contract with UnitedHealthcare.
Here's Why You Should Hold on to Edwards Lifesciences for Now
by Zacks Equity Research
Investors continue to be upbeat about Edwards Lifesciences (EW) owing to its strong segmental growth and robust product demand.
QIAGEN's (QGEN) Selloff Deal With Thermo Fisher Progresses
by Zacks Equity Research
QIAGEN's (QGEN) acquisition deal with Thermo Fisher receives approval from QIAGEN shareholders.
4 Cheap MedTech Stocks Poised to Beat Industry Post-Pandemic
by Debanjana Dey
Here are some MedTech stocks which might be a solid investment option post the coronavirus blues.
Abbott, Tandem Diabetes Seal Deal on Diabetes Management
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre CGM technology to be integrated with Tandem Diabetes' insulin pumps to enhance diabetes care.
LabCorp's Xcellerate Coronavirus Solution to Aid Clinical R&D
by Zacks Equity Research
This solution by LabCorp (LH) takes the idea from Covance's COVID-19 Operational Recovery Team to better understand the necessities.
Bio-Rad Rides on PCR Test Kits for Coronavirus Amid Cost Woe
by Zacks Equity Research
The uptick in Bio-Rad's (BIO) core PCR and Droplet Digital PCR product revenues is the result of robust demand due to coronavirus testing and related research.
Zacks.com featured highlights include: Keurig Dr Pepper, Hologic, Meritage Homes, Vistra Energy and Sally Beauty
by Zacks Equity Research
Zacks.com featured highlights include: Keurig Dr Pepper, Hologic, Meritage Homes, Vistra Energy and Sally Beauty